Skip to main content
ZBH logo

Zimmer Biomet Holdings, Inc. (ZBH) Stock: Price, Forecast & Analyst Target

Zimmer Biomet Holdings, Inc. (ZBH) — MoonshotScore 79/100 (Strong band), calculated Nov 18, 2026. Price $101.47 (-1.79%), as of the Nov 19, 2026 trading session; market cap $19.2B. Expected results Feb 9, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$101.47 −$1.85 (-1.79%) Market Cap $19.2B

Zimmer Biomet Holdings, Inc. · ZBH · NYSE · Healthcare · Medical - Devices

Research dated 2026-09-12: Zimmer Biomet sells orthopedic reconstruction systems led by knee and hip products, alongside sports medicine, trauma, extremities, spine, dental and related surgical offerings across major global regions. The unresolved tension is whether spending on the United States commercial organization can translate product demand into durable growth without prolonging margin pressure.

Price as of Nov 19, 2026

Key Statistics

79 of 100

MoonshotScore v2 · Zimmer Biomet Holdings (ZBH)

Strong
Business Quality Elite (82)
Financial Safety Okay (41)
Valuation Fair (72)
Growth Durability Compounding (80)
Momentum Surging (83)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 9, 2027
  • Altman Z 2.40 · Piotroski F 7

Helping: business quality, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ZBH (57 recorded, newest six shown)
RecordedScoreBand
81Exceptional
80Exceptional
80Exceptional
80Exceptional
79Strong
79Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$101.47
Change on the day-1.79%
52-week range$79.12–$112.55
Market capitalisation$19.2B—
Price / earnings (trailing)25.72
Shares traded on the day1.85M
Beta (volatility vs the S&P 500)0.47

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $82, high $106, latest $101. $106 $82 high $106 Oct 17, 2025 Nov 19, 2026 · $101 $102Oct 17, 2025$101Oct 31, 2025$90Nov 14, 2025$98Nov 28, 2025$92Dec 12, 2025$91Dec 26, 2025$93Jan 9, 2026$87Jan 23, 2026$90Feb 6, 2026$99Feb 20, 2026$94Mar 6, 2026$88Mar 20, 2026$91Apr 2, 2026$95Apr 17, 2026$83May 1, 2026$84May 15, 2026$82May 29, 2026$89Jun 12, 2026$93Jun 26, 2026$91Jul 10, 2026$91Jul 24, 2026$97Aug 7, 2026$101Aug 21, 2026$98Sep 4, 2026$95Sep 18, 2026$88Oct 2, 2026$95Oct 16, 2026$95Oct 30, 2026$103Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Zimmer Biomet Holdings (ZBH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Strong
Momentum Strong

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Neutral
Debt/Equity Weak
ROE Neutral
Gross Margin Strong

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Zimmer Biomet Holdings (ZBH), and what does it report?

Short answer · as of

Zimmer Biomet is an orthopedic reconstruction specialist rather than a general hospital-equipment vendor.

It designs, manufactures and markets products used in joint reconstruction and related surgical fields, so revenue reflects demand for implants and surgical products across procedures and markets.

Reporting uses a geographic lens across the Americas, Europe, the Middle East, Africa and Asia Pacific, while the product view separates knees, hips and S E T. Knees form the largest disclosed product pool, making joint reconstruction more important to the revenue mix than the broad medical-device label suggests.

2 · Latest results

What do the latest results show for Zimmer Biomet Holdings (ZBH)?

The latest quarter delivered higher revenue and gross profit than the preceding period and the comparable prior period. Operating profit, net income and diluted earnings per share retreated sequentially but improved against the comparable period, showing that growth has not yet produced a smooth profit progression.

Estimate comparisons use an adjusted earnings series that sits above reported diluted earnings per share, so an earnings beat and the statutory profit trend answer different questions. Management raised its organic constant-currency revenue outlook and expects foreign exchange to help reported growth, while forecasting further operating-margin pressure from investment in the United States commercial organization. Selling and administrative expense rose sequentially and against the comparable period, consistent with that explanation without proving causation.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2.00B$231M$1.16 (diluted)
Q4 FY2025$2.24B$139M—
Q1 FY2026$2.09B$238M$1.22 (diluted)
Q2 FY2026$2.18B$198M$1.03 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Zimmer Biomet Holdings (ZBH)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow remained positive throughout the reported series and strengthened in the latest quarter against the preceding and comparable periods. Liquidity ratios remain above parity, free cash flow is meaningful relative to market value, and the regular dividend has continued at an unchanged recent rate.

The balance sheet is nevertheless far from a net-cash position. Debt vastly exceeds cash and short-term investments, while cash ended below its level at the start of the reported window despite considerable fluctuations between periods. Rising annual revenue accompanied falling net income in the latest year, so sustained cash conversion matters more than revenue growth alone when assessing the leverage burden.

4 · What to check next?

What should you watch next at Zimmer Biomet Holdings (ZBH)?

Short answer · as of

The next earnings report is expected on Feb 9, 2027.

At the scheduled earnings release, separate organic constant-currency growth from the expected foreign-exchange benefit. Operating margin and selling expense deserve particular attention because management has guided to a further sequential margin decline while attributing pressure to commercial investment.

Adjusted earnings have met or exceeded estimates throughout the displayed history, while revenue recorded an isolated miss. Continued beats would carry less information than evidence that reported operating profit and operating cash flow are strengthening alongside sales. Longer-range consensus assumes rising revenue and earnings per share, making progress in knees, hips and S E T—and either a cash rebuild or debt reduction—the more useful confirmation points.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Zimmer Biomet Holdings compare with its peers?

Short answer

Zimmer Biomet Holdings's score ranks 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Zimmer Biomet belongs beside diversified orthopedic reconstruction businesses, not broad device makers centered on diagnostics or monitoring. Its disclosed mix is anchored by knees, followed by hips and S E T, while geographic reach spans major markets across the Americas, Europe, the Middle East, Africa and Asia Pacific.

That combination concentrates the economics around musculoskeletal procedures despite broad geographic coverage. Gross profitability is substantial, but current commercial spending is pressing operating margin, so comparison with similar businesses should emphasize conversion of gross profit into operating profit and cash after selling and research expense rather than sales growth in isolation.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Globus Medical, Inc. (GMED) Same industry, near in market value$70.53 Nov 18, 2026$9.34B94 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Edwards Lifesciences Corporation (EW) Same industry, near in market value$105.23 Nov 18, 2026$60.5B93 5-pillar Nov 18, 2026
Penumbra, Inc. (PEN) Same industry, near in market value$320.00 Nov 19, 2026$12.6B92 5-pillar Nov 18, 2026
STERIS plc (STE) Named competitor$259.57 Nov 18, 2026$25.2B87 5-pillar Nov 18, 2026
Insulet Corporation (PODD) Same industry, near in market value$139.98 Nov 18, 2026$9.71B85 5-pillar Nov 18, 2026
Smith & Nephew plc (SNN) Same industry, near in market value$29.83 Nov 19, 2026$12.5B84 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Same industry, near in market value$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Zimmer Biomet Holdings (ZBH) — this page$101.47$19.2B79
Koninklijke Philips N.V. (PHG) Same industry, near in market value$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Bio-Rad Laboratories, Inc. (BIO) Same industry, near in market value$370.17 Nov 18, 2026$9.95B77 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Named competitor$258.99 Nov 19, 2026$28.5B74 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$93.00 – $140.00
Consensus target
$112.00
Median target
$112.00

Consensus record · Captured .

Measured against a quoted price of $101.47 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026

Transactions
28
Identified insiders
12
Purchases
0
Sales
4
Other transactions
24

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ZBH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ZBH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Zimmer Biomet Holdings (ZBH)?

Read these with our analysis →

Common Questions About ZBH (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why are knees so important to Zimmer Biomet?

Knees are Zimmer Biomet’s largest disclosed product revenue category, ahead of hips and S E T. Their scale means changes in knee-product demand can materially shape companywide growth even though the portfolio extends across many orthopedic and surgical fields.

Why can Zimmer Biomet revenue rise while reported earnings fall?

Revenue and gross profit can advance while selling expense absorbs more of the gain. The latest sequential comparison shows exactly that pattern, and management links expected operating-margin pressure to investment in the United States commercial organization.

Why do Zimmer Biomet’s adjusted and diluted earnings differ?

The estimate history compares an adjusted earnings measure, while the income statement presents diluted earnings under the reported accounting basis. An estimate beat therefore does not mean reported net income or diluted earnings improved sequentially.

Why does Zimmer Biomet report by geography when knees lead product revenue?

The geographic segments show where Zimmer Biomet operates, while the product categories show what generates sales. Reading them together reveals a globally distributed business whose disclosed product mix remains concentrated in joint reconstruction.

What is the ZBH stock price today?

The last price recorded for Zimmer Biomet Holdings, Inc. (ZBH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ZBH price target?

The analyst consensus price target for Zimmer Biomet Holdings, Inc. (ZBH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Management outlook — dated call excerpts
  • 1. What is Zimmer Biomet Holdings (ZBH), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Zimmer Biomet Holdings (ZBH)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Zimmer Biomet Holdings (ZBH)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Recent dividends paid; Next scheduled dividend
  • 4. What should you watch next at Zimmer Biomet Holdings (ZBH)?: Next earnings report; Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Revenue by segment; Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How does Zimmer Biomet Holdings compare with its peers?: Business description; Revenue by segment; Trailing twelve-month ratio set; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • FAQ: Why are knees so important to Zimmer Biomet?: Revenue by segment; Business description
  • FAQ: Why can Zimmer Biomet revenue rise while reported earnings fall?: Quarterly income statement (USD thousands); Management outlook — dated call excerpts
  • FAQ: Why do Zimmer Biomet’s adjusted and diluted earnings differ?: Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands)
  • FAQ: Why does Zimmer Biomet report by geography when knees lead product revenue?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ZBH

Funds in our ETF coverage that list ZBH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
LGHT ETF4.23%